close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Unicycive Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY
Via NewMediaWire
Topics Fraud Lawsuit
Tickers UNCY
Exposures Financial Legal Product Safety
Unicycive Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers UNCY
Exposures Financial Legal Product Safety
Levi &amp; Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Via TheNewswire.com
Topics Earnings Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi &amp; Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Via NewMediaWire
Topics Earnings Fraud Lawsuit
Tickers CYTK
Exposures Financial Legal Product Safety
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via NewMediaWire
Topics Fraud Lawsuit
Tickers REPL
Exposures Financial Legal Product Safety
Levi &amp; Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers REPL
Exposures Financial Legal Product Safety
FDA Expands Incyte's Opzelura Approval To Treat Atopic Dermatitis In Children
Via Benzinga
Tickers INCY
Exposures Product Safety
Executive Standard Sanitation Launches Innovative Employee Support Program
Via Press Release Distribution Service
Topics Product Recall Retirement
Exposures COVID-19 Legal Pension
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
Via TheNewswire.com
Tickers ABVC
Exposures Product Safety
ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model
Via NewMediaWire
Tickers ABVC
Exposures Product Safety
Wind Noise In Your Ford Taurus? It Could Be a Recall Alert You Can't Ignore
Via Benzinga
Topics Product Recall
Tickers F TSLA
Exposures Legal Product Safety
Why Replimune Stock Plummeted by Almost 40% Today
Via The Motley Fool
Tickers BMY REPL
Exposures Product Safety
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything
Via MarketBeat
Tickers LLY
Exposures Product Safety
Intuitive Surgical: A Steady Hand in a Storm of AI Hype?
Via MarketMinute
Topics Artificial Intelligence Supply Chain
Tickers ISRG JNJ MDT MSFT NVDA
Exposures Artificial Intelligence Product Safety Supply Chain
How students can get the internet connectivity they need
Via Brandpoint
Topics Product Recall
Tickers TMUS
Exposures Legal Product Safety
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
Via Benzinga
Topics ETFs
Tickers HEAL HIMS LLY NVO PTH THNR
Exposures Product Safety
Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA
Via Benzinga
Tickers ABT DXCM
Exposures Product Safety
Shareholders of Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRA
Via NewMediaWire
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
Shareholders That Lost Money on Unicycive Therapeutics, Inc. (UNCY) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Via NewMediaWire
Topics Fraud Lawsuit
Tickers UNCY
Exposures Financial Legal Product Safety
Levi & Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via NewMediaWire
Topics Fraud Lawsuit
Tickers REPL
Exposures Financial Legal Product Safety
Shareholders That Lost Money on Unicycive Therapeutics, Inc. (UNCY) Urged to Join Class Action - Contact Levi &amp; Korsinsky to Learn More
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers UNCY
Exposures Financial Legal Product Safety
Levi &amp; Korsinsky Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 22, 2025 - REPL
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers REPL
Exposures Financial Legal Product Safety
Shareholders of Savara Inc. Should Contact Levi &amp; Korsinsky Before November 7, 2025 to Discuss Your Rights - SVRA
Via TheNewswire.com
Topics Fraud Lawsuit
Tickers SVRA
Exposures Financial Legal Product Safety
Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy
Via Investor's Business Daily
Tickers LLY NVO
Exposures Product Safety
Why Is Everyone Talking About Novo Nordisk Stock?
Via The Motley Fool
Tickers LLY NVO
Exposures Product Safety
1 Large-Cap Stock Worth Your Attention and 2 We Find Risky
Via StockStory
Tickers DXCM PFE TFC
Exposures Product Safety
Calm Little Minds Launches Educational Tools for Child Emotional Well-being
Via Press Release Distribution Service
Topics Product Recall
Exposures Legal Product Safety
YJ Labs and Research Announces New Approach to Mind Body Transformation
Via Press Release Distribution Service
Topics Product Recall
Exposures Legal Product Safety
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today